Allied (ALID) 10-Q 14 Jan 25 2025 Q1 Quarterly report Financial data

Cover

Cover	3 Months Ended
	Nov. 30, 2024 shares
Cover [Abstract]
Entity Registrant Name	Allied Corp.
Entity Central Index Key	0001575295
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Nov. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding	115,495,384
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56002
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	33-1227173
Entity Address Address Line 1	200-460 Doyle Ave
Entity Address Address Line 2	Suite 201
Entity Address City Or Town	Kelowna
Entity Address State Or Province	BC
Entity Address Country	CA
Entity Address Postal Zip Code	V1Y OC2
City Area Code	877
Local Phone Number	255-4337
Entity Interactive Data Current	Yes

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Nov. 30, 2024	Aug. 31, 2024
Current assets
Cash	$ 195,350	$ 359,103
Inventory (Note 3)	287,053	261,016
Accounts receivable	75,939	47,955
Prepaid expenses	54,127	45,485
Total current assets	612,469	713,559
Deposits and advances (Note 5)	17,558	20,668
Right-of-use assets (Note 9)	120,114	131,865
Property, plant and equipment (Note 6)	1,173,224	1,218,111
Intangible assets (Note 7)	27,149	30,638
Total assets	1,950,514	2,114,841
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable and accrued liabilities	2,758,604	2,703,163
Due to related parties (Note 13)	122,873	353,513
Current portion of lease liabilities (Note 9)	17,239	17,090
Loans payable (Note 10)	2,813,600	2,699,641
Secured convertible notes payable (Note 11)	3,774,891	3,774,891
Total current liabilities	9,487,207	9,548,298
Non-current liability
Lease liabilities, net of current portion (Note 9)	103,751	115,007
Total liabilities	9,590,958	9,663,305
Common stock - 300,000,000 shares authorized, $0.0001 par value; 115,495,384 shares issued and outstanding August 31, 2024 - 112,471,472)	11,550	11,248
Additional paid in capital	43,272,117	42,613,696
Common stock issuable	30,000	30,000
Accumulated deficit	(50,364,810)	(49,584,520)
Accumulated other comprehensive loss	(589,301)	(618,888)
Total stockholders' deficit	(7,640,444)	(7,548,464)
Total liabilities and stockholders' deficit	$ 1,950,514	$ 2,114,841

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Nov. 30, 2024	Aug. 31, 2024
Condensed Consolidated Interim Balance Sheets
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares issued	115,495,384	112,471,472
Common stock, shares outstanding	115,495,384	112,471,472

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss
Sales	$ 27,669	$ 19,039
Cost of sales	(14,058)	(2,003)
Gross margin	13,611	17,036
Amortization and depreciation	33,343	35,419
Consulting fees (Note 13)	173,808	441,487
Office and miscellaneous	208,331	152,822
Professional fees	112,833	60,789
Convertible note interest	94,114	118,646
Operating expenses	622,429	809,163
Loss before other items	(608,818)	(792,127)
Other income (expenses):
Interest expense and bank charges	(123,543)	(92,867)
Foreign exchange loss	(47,929)	48,321
Net loss	(780,290)	(836,673)
Foreign currency translation adjustment	29,587	(16,622)
Comprehensive loss	$ (750,703)	$ (853,295)
Loss per share - basic and diluted	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding - basic and diluted	113,437,620	102,861,018

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Operating activities:
Net loss for the year	$ (780,290)	$ (836,673)
Adjustments for non-cash items:
Accrued interest	217,038	210,790
Amortization and depreciation	33,343	35,419
Stock-based compensation - options	53,941	143,653
Adjustments for changes in working capital:
Inventory	(10,864)	(82,277)
Other receivables	(27,984)	(20,277)
Prepaid expenses	(8,642)	(676)
Deposits and advances	3,110	2,437
Accounts payable and accrued liabilities	35,628	(37,695)
Payments of lease liabilities	8,585	0
Due to related parties	(15,858)	118,920
Net cash used in operating activities	(509,163)	(466,379)
Investing activities:
Purchases of property, plant and equipment	(37,394)	0
Net cash used in investing activities	(37,394)	0
Financing activities:
Repayment of loan payable	(8,965)	0
Proceeds from the issuance of common stock	390,000	0
Proceeds for subscriptions of stock issuable	0	346,000
Net cash provided by financing activities	381,035	346,000
Effect of exchange rate on changes of cash	1,769	(49,763)
Net change in cash	(165,522)	(120,379)
Cash, beginning of period	359,103	209,736
Cash, end of period	195,350	39,594
Supplemental cash flow disclosures:
Income taxes paid	0	0
Interest paid	$ 4,682	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders Deficit - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Issuable [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance, shares at Aug. 31, 2023		101,592,914
Balance, amount at Aug. 31, 2023	$ 6,884,463	$ 10,160	$ 39,404,667	$ 80,000	$ 45,608,336	$ 770,954
Shares issued for cash, shares		250,000
Shares issued for cash, amount	0	$ 25	49,975	50,000	0	0
Shares subscribed	346,000	0	0	346,000	0	0
Stock-based compensation	143,653	0	143,653	0	0	0
Comprehensive loss for the period	(853,295)	$ 0	0	0	836,673	16,622
Balance, shares at Nov. 30, 2023		101,842,914
Balance, amount at Nov. 30, 2023	7,248,105	$ 10,185	39,598,295	376,000	46,445,009	787,576
Balance, shares at Aug. 31, 2023		101,592,914
Balance, amount at Aug. 31, 2023	$ 6,884,463	$ 10,160	39,404,667	80,000	45,608,336	770,954
Shares issued for cash, shares	10,181,990
Balance, shares at Aug. 31, 2024		112,471,472
Balance, amount at Aug. 31, 2024	$ (7,548,464)	$ 11,248	42,613,696	30,000	49,584,520	618,888
Shares issued for cash, shares	1,073,912	1,950,000
Shares issued for cash, amount	$ 390,000	$ 195	389,805	0	0	0
Stock-based compensation	53,941	0	53,941	0	0	0
Comprehensive loss for the period	(750,703)	$ 0	0	0	780,290	29,587
Shares issued on stock option exercise, shares		1,073,912
Shares issued on stock option exercise, amount	214,782	$ 107	214,675	0	0	0
Balance, shares at Nov. 30, 2024		115,495,384
Balance, amount at Nov. 30, 2024	$ (7,640,444)	$ 11,550	$ 43,272,117	$ 30,000	$ 50,364,810	$ 589,301

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN	3 Months Ended
	Nov. 30, 2024
NATURE OF OPERATIONS AND GOING CONCERN
NATURE OF OPERATIONS AND GOING CONCERN	1. NATURE OF OPERATIONS AND GOING CONCERN a) Nature of operations Allied Corp. (the “Company” or “Allied”) was incorporated in the State of Nevada on February 3, 2013, and officially adopted its current name on July 1, 2019. The Company's head office and registered office are located at 200-460 Doyle Ave, Kelowna, British Columbia, V1Y OC2, Canada. The Company’s common shares trade on the OTCQB under the symbol “ALID”. On February 18, 2020, the Company acquired all issued and outstanding share capital of Allied Colombia, a Colombian entity. Allied Colombia’s assets, liabilities, and results have been consolidated into these financial statements from the date of acquisition. As of August 31, 2024, Allied Colombia operates a licensed cannabis farm in Colombia. Allied’s business plan includes the discovery of new medical technologies, some of which are cannabis-derived, aimed at providing comprehensive therapy and support for trauma survivors, military veterans, and first responders. However, the Company has not yet begun such operations or obtained the necessary permits. Its current revenue is derived from the sale of cannabis products through Allied Colombia. b) Going concern The unaudited condensed consolidated interim financial statements for the three months ended November 30, 2024 and 2023 (the “financial statements”) have been prepared on a going concern basis. For the three months ended November 30, 2024, the Company incurred a net loss of $780,290 (2023 - $836,673), generated minimal revenue, and did not achieve positive operating cash flows. As at November 30, 2024, the Company had a working capital deficit of $8,874,738 (August 31, 2024 - $8,834,739). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not reflect any adjustments related to the potential recoverability and classification of recorded assets, or the amounts and classifications of liabilities, which could be required if the Company is unable to continue as a going concern. The Company’s ability to continue relies on raising sufficient financing to acquire or develop a profitable business. Management plans to fund operations and future development primarily through equity sales, supplemented by related party loans, until future operations can generate sufficient funds to meet working capital needs. c) Business Risks While some states in the United States have authorized the use and sale of cannabis, it remains illegal under federal law and the approach to enforcement of U.S. federal laws against cannabis is subject to change. The Company plans to engage in cannabis-related activities in the United States, only if and when cannabis operations are federally legalized. On January 4, 2018, the then United States Attorney General Jeff Sessions issued a memorandum to United States district attorneys (the “Sessions Memorandum”) which rescinded previous guidance from the United States Department of Justice specific to cannabis enforcement in the United States, including the Cole Memorandum. With the Cole Memorandum rescinded, United States federal prosecutors no longer have guidance relating to the exercise of their discretion in determining whether to prosecute cannabis related violations of United States federal law. Since that time, United States district attorneys have taken no legal action against state law compliant entities, and the Biden administration is generally anticipated to seek federal decriminalization of state legal cannabis activity. Nevertheless, a significant change in the federal government’s enforcement policy with respect to current federal laws applicable to cannabis could cause significant financial damage to the Company. The Company may be irreparably harmed by a change in enforcement policies of the federal government depending on the nature of such change. Given the current illegality of cannabis under United States federal law, the Company’s ability to access both public and private capital may be hindered by the fact that certain financial institutions are regulated by the United States federal government and are thus prohibited from providing financing to companies engaged in cannabis related activities. The Company’s ability to access public capital markets in the United States is directly hindered as a result. The Company may, however, be able to access public and private capital markets in the United States through institutions which are not regulated by the United States federal government, in Canada, and in many other countries in order to support continuing operations.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Nov. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Business Presentation These unaudited condense consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States dollars. The Company’s fiscal year end is August 31. These interim unaudited financial statements have been prepared in accordance with US GAAP for interim financial information and with the instructions to Securities and Exchange Commission (“SEC”) Form 10-Q. They do not include all of the information and footnotes required by US GAAP for complete financial statements. Therefore, these interim financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended August 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the SEC. The consolidated financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at November 30, 2024, and the results of its operations for the three months ended November 30, 2024, and cash flows for the three months ended November 30, 2024. The results of operations for the period ended November 30, 2024 are not necessarily indicative of the results to be expected for future quarters or the full year. The significant accounting policies followed are: a) Principles of consolidation These financial statements include accounts of Allied Corp. and its wholly-owned subsidiaries, including AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd. and Allied Colombia. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation. b) Foreign currency translation Foreign currency transactions are translated into U.S. dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rate at the reporting date. All differences are recorded in the consolidated statements of income and comprehensive income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. Assets and liabilities of foreign operations are translated into U.S. dollars at year-end exchange rates and any revenue and expenses are translated at the average exchange rate for the year. The resulting exchange differences are recognized in other comprehensive income. c) Cash Cash is comprised of cash on hand, cash held in trust accounts and demand deposits. d) Taxes receivable Taxes receivable represent payments of VAT and are presented as part of other receivables. On a periodic basis, the Company assess recoverability of these balances based on the probability of the Colombian government to reimburse these amounts. e) Inventory Inventory includes work-in-progress and finished goods. Work-in-progress comprises raw materials, supplies, pre-harvest cannabis plants, and diluted crude. Finished goods consist of dried flower, CBD isolates available for sale, and purchased cannabis products. The costs of inventory include but are not limited to labor, utilities, nutrition and irrigation, overhead and the depreciation of manufacturing equipment and production facilities, and amortization of licenses determined at normal capacity. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and rent of grow facility. The Company began production in Colombia in late 2020, when the Company obtained approval for its strains of products. During the current period, certain costs were determined based on the actual usage of production space as compared to the normal predetermined operational production of the facility based on capacity as the Company gradually started to grow products and prepared the facility ready. Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s consolidated balance sheets, statements of net loss and comprehensive loss and statements of cash flows. f) Property, plant and equipment Property, plant, and equipment are recorded at cost, net of accumulated depreciation and impairment losses. Depreciation is calculated on a straight-line basis over the assets’ estimated useful lives, which are as follows: Category Useful life Farm facility and equipment 1 - 10 years Office and computer equipment 5 - 10 years Land equipment 10 years g) Intangible assets Intangible assets consist of licenses, amortized on a straight-line basis over the shorter of their estimated economic life of 10 years or their legal life. Amortization of licenses begins from the acquisition date. The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives. h) Impairment of long-lived assets Long-lived assets include property and equipment, right-of-use assets, and intangible assets with finite useful lives. At each balance sheet date or when triggering events arise, the Company assesses long-lived assets for potential impairment. Assets are grouped at the lowest level of separately identifiable cash flows, or asset groups. Circumstances that may trigger an impairment review include significant declines in the asset's market price, adverse changes in business climate or legal factors, substantially higher than expected acquisition or construction costs, current period or projected operating losses associated with the asset, and expectations of early asset disposal. If impairment indicators are present, the Company conducts an undiscounted cash flow analysis to assess recoverability. Impairment losses are recognized in profit or loss to the extent that an asset’s carrying amount exceeds its fair value. i) Leases At the start of a contract containing a lease, the Company classifies leases other than short-term leases as either operating or finance leases, following the criteria outlined in ASU 2016-02 Leases For both finance and operating leases, right-of-use assets and lease liabilities are initially measured as the present value of future lease payments plus initial direct costs, discounted at the lease's implicit interest rate, or, if not available, the Company’s incremental borrowing rate. Subsequent measurements differ by lease type: · For finance leases, lease liabilities are measured at amortized cost using the effective interest rate method, and right-of-use assets are measured at cost less accumulated amortization, depreciated on a straight-line basis over the lease term. · For operating leases, lease liabilities are measured at the present value of unpaid lease payments, discounted at the original discount rate. Right-of-use assets are adjusted by accumulated amortization, calculated as the difference between the straight-line lease cost (including amortization of initial direct costs) and the periodic accretion of the lease liability. As at November 30, 2024, the Company has one lease which is classified as an operating lease. j) Stock-based compensation The Company measures equity-settled share-based payments at fair value on the grant date, recognizing share-based compensation expense over the vesting period based on the estimated number of equity instruments expected to vest and uses Plain Vanilla for calculating the expected terms of options. Any consideration received from stock option exercises is recorded as an increase to common stock and additional paid-in capital. k) Share issuance costs Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued. l) Secured convertible notes payable Under the simplified guidance of ASU 2020-06, the Company accounts for convertible debt instruments, including its secured convertible notes payable as a single unit of account unless the conversion feature requires bifurcation in accordance with derivative accounting under ASC 815. Secured convertible notes payable are initially recorded at fair value adjusted for issuance costs and subsequently measured at amortized cost using the effective interest method. Convertible note interest expense includes the stated interest rate and any applicable amortized discounts. Upon conversion, the debt's carrying amount is reclassified to equity with no gain or loss recognized. m) Financial instruments Financial instruments represent contracts that create a financial asset for one party and a financial liability or equity instrument for another. Initially, financial instruments are recorded at fair value, reflecting the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Subsequent measurement depends on the classification of the financial instrument, with values measured at either fair value or amortized cost. For instruments measured at fair value, the Company uses quoted market prices when available to determine fair value. Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy, based on the reliability of the lowest level of inputs used in estimating fair values. The three levels of the fair value hierarchy are as follows: Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices); and Level 3 - Inputs that are not based on observable market data. The Company’s financial instruments comprise cash, trade receivables, accounts payable, accrued liabilities, loans payable, and secured convertible notes payable. There are no financial assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet. As of November 30, 2024, the carrying values of the Company’s financial instruments approximate their fair values, primarily due to their short-term maturities. n) Revenue recognition The Company’s revenue is comprised of sales of cannabis products. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data. o) Net income (loss) per common share Net income (loss) per share is calculated in accordance with ASC 260 Earnings per Share Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding. p) Income taxes The Company accounts for income taxes under ASC 740 Income Taxes A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. q) Related party transactions Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts. r) Significant accounting estimates and judgments The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company’s ability to continue to as going concern as described in Note 1. s) Recent accounting pronouncements Issuance of ASU 2020-06: In August 2020, the Financial Accounting Standards Board (FASB) issued ASU 2020-06 - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging and Contracts in Entity’s Own Equity (Subtopic 815-40) Additionally, the new standard introduces enhanced disclosures for convertible debt and freestanding instruments indexed to and settled in an entity’s own equity. It also amends the diluted earnings per share guidance, mandating the use of the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2022, and must be applied on a full or modified retrospective basis, with early adoption allowed starting January 1, 2021. Issuance of ASU 2023-07: In November 2023, the FASB issued ASU 2023-07, which introduces improvements to the information that a public entity discloses about its reportable segments and addresses investor requests for more information about reportable segment expenses. The ASU does not change the current guidance related to the identification of operating segments, the determination of reportable segments, or the aggregation criteria. Rather, the new guidance introduces additional disclosure requirements and expands those requirements to entities with a single reportable segment, not just entities with multiple reportable segments. ASU 2023-07 enhances interim disclosure requirements, clarifies the circumstances in which an entity can disclose multiple segment measures of profit or loss, and introduces the significant expense principle, which requires additional disclosure of segment expenses. In addition, the ASU provides new segment disclosure requirements for entities with a single reportable segment and contains other disclosure requirements. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The Company will adopt ASU 2023-07 for effective September 1, 2024 and the effects will be present in the Company’s financial statements the fiscal year ended August 31, 2025 and all interim periods following. The Company has not early-adopted any new accounting standard, interpretation or amendment that has been issued but is not yet effective other than ASU 2020-06. The adoption of ASU 2020-06 did not have a material impact. t) Reclassification and change in presentation of comparative figures Certain amounts on the Condensed Consolidated Interim Statements of Operations and Comprehensive Loss of the prior year have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.

INVENTORY

INVENTORY	3 Months Ended
	Nov. 30, 2024
INVENTORY
INVENTORY	3. INVENTORY Inventory is comprised of the following items: November 30, 2024 August 30, 2024 Work in progress $ 104,720 $ 132,508 Finished goods 182,333 128,508 $ 287,053 $ 261,016 Inventory as at November 30, 2024 is presented net of a net realizable value adjustment of $67,977 (August 31, 2024 - $417,862). During the three months ended November 30, 2024, the Company recognized an inventory write-off of $67,977 due to obsolescence (2023 - $417,862), recorded within cost of sales.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	3 Months Ended
	Nov. 30, 2024
ACCOUNTS RECEIVABLE
ACCOUNTS RECEIVABLE	4. ACCOUNTS RECEIVABLE A summary of the Company’s accounts receivable is as follows: November 30, 2024 August 31, 2024 Trade receivables $ 70,585 $ 47,955 Tax receivables 5,354 - $ 75,939 $ 47,955

DEPOSITS AND ADVANCES

DEPOSITS AND ADVANCES	3 Months Ended
	Nov. 30, 2024
DEPOSITS AND ADVANCES
DEPOSITS AND ADVANCES	5. DEPOSITS AND ADVANCES November 30, 2024 August 31, 2024 Prepayments for construction facility in Colombia $ 17,558 $ 20,668 Total deposits and advances $ 17,558 $ 20,668 As at November 30, 2024 and August 31, 2024, deposits and advances were $17,558 and $20,668, respectively, representing payments made to vendors for the construction of farm facilities in Colombia.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Nov. 30, 2024
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT	6. PROPERTY, PLANT AND EQUIPMENT A summary of the Company’s property, plant and equipment as at November 30, 2024 and August 31, 2024 is as follows: November 30, 2024 August 31, 2024 Construction in process $ 416,706 $ 419,592 Farm facility and equipment 1,310,889 1,332,215 Office and computer equipment 27,739 29,244 Land equipment 27,227 28,827 1,782,561 1,809,878 Less: accumulated depreciation 609,337 591,767 Property, plant and equipment, net $ 1,173,224 $ 1,218,111 During the three months ended November 30, 2024, the Company recorded depreciation of $42,082 (2023 - $56,676), and foreign currency translation loss of $40,199 (2023 – foreign currency translation gain of $16,012). As at November 30, 2024, depreciation of $15,173 was included in inventory (August 31, 2024 - $74,814).

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Nov. 30, 2024
INTANGIBLE ASSETS
INTANGIBLE ASSETS	7. INTANGIBLE ASSETS A summary of the Company’s intangible assets as at November 30, 2024 and August 2024 is as follows: November 30, 2024 August 31, 2024 Intangible assets $ 4,198,891 $ 4,445,619 Less: accumulated amortization 969,512 1,024,585 Less: accumulated impairment 3,202,230 3,390,396 Intangible assets, net $ 27,149 $ 30,638 During the three months ended November 30, 2024, the Company recorded amortization expense and impairment of $1,851 and $nil, respectively (2023 - $1,437 and $nil, respectively), and foreign currency translation loss of $1,638 (2023 – $388).

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	3 Months Ended
	Nov. 30, 2024
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES A summary of the Company’s accounts payable and accrued liabilities as at November 30, 2024 and August 2024 is as follows: November 30, 2024 August 31, 2024 Trade payable $ 854,232 $ 832,870 Accrued liabilities 1,904,372 1,870,293 $ 2,758,604 $ 2,703,163

LEASES

LEASES	3 Months Ended
	Nov. 30, 2024
LEASES
LEASES	9. LEASES The Company accounts for leases under ASC 842, Leases, which establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. The Company also elected to keep all leases with an initial term of 12 months or less off the balance sheet. As at August 31, 2023, the Company had one active lease for a 12.5-hectare plot of land in Los Santos Municipality, Colombia, designated for cultivation activities. The lease was set to expire on February 1, 2030. This lease was classified as an operating lease. On August 1, 2024, the Company and the lessor amended the lease, increasing the base rent and adjusting the lease term to expire on July 31, 2029. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the ROU asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the ROU asset results in front-loaded expense over the lease term. ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. At August 31, 2023, the Company did not have any finance leases. A summary of the Company’s weighted average discount rate used in calculating lease liabilities and weighted average remaining lease term is as follows: November 30, 2024 August 31, 2024 Weighted average discount rate 15 % 15 % Weighted average remaining lease term 4.67 years 4.92 years The components of lease expenses were as follows: Operating lease cost: Amortization of right-of-use assets $ 4,583 Interest expense on lease liabilities 4,682 Total operating lease cost $ 9,265 For the three months ended November 30, 2024, the Company incurred total operating lease cost of $9,265 (2023 - $6,610). Lease payments on the Company’s operating lease for the three months ended November 30, 2024 were $8,585 (2023 - $6,610). A summary of the maturity of contractual undiscounted liabilities associated with the Company’s operating leases as at November 30, 2024 is as follows: Year ending August 31, 2025 $ 25,067 2026 35,231 2027 36,606 2028 36,579 2029 34,658 Total minimum lease payments 168,141 Less: amount of lease payments representing effects of discounting (47,151 ) Present value of minimum lease payments 120,990 Less current portion of lease liability (17,239 ) Lease liabilities, non-current portion $ 103,751

LOANS PAYABLE

LOANS PAYABLE	3 Months Ended
	Nov. 30, 2024
LOANS PAYABLE
LOANS PAYABLE	10. LOANS PAYABLE A continuity of the Company’s loans payable as at November 30, 2024 and August 2024 is as follows: Loan for prefabricated buildings financing Loan for equipment purchase financing Related party loans Other cash advance Total August 31, 2023 $ 1,742,648 $ 284,700 $ - $ - $ 2,027,348 Additions - - 100,600 100,000 200,600 Interest expense 451,358 20,335 - - 471,693 August 31, 2024 2,194,006 305,035 100,600 100,000 2,699,641 Additions - - 1,035 - 1,035 Repayment - - (10,000 ) - (10,000 ) Interest expense 112,840 5,084 5,000 - 122,924 November 30, 2024 $ 2,306,846 $ 310,119 $ 96,635 $ 100,000 $ 2,813,600 a) Loan for prefabricated buildings financing In June 2020, the Company secured a financing agreement to fund the purchase of prefabricated buildings intended for potential cannabis operations. Under the agreement, the Company borrowed $1,253,772, with an original maturity date of November 20, 2020. This date was extended through several amendments, with the most recent in June 2022, establishing a current maturity date of September 1, 2024. The revised payment terms require monthly payments of $37,613 for the first three months starting July 1, 2022, followed by monthly payments of $66,288 for the remaining period. These payments include interest at a monthly rate of 3%. For the three months ended November 30, 2024, no interest was paid (2023 - $nil) and the loan accrued interest payable of $112,840 (2023 - $112,840). b) Loan for equipment purchase financing On December 17, 2021, the Company entered into a financing agreement to fund an equipment purchase. The Company borrowed $295,543 at an interest rate of 8% per annum. The equipment financing loan required the Company to make monthly payments of $15,000 with a final balloon payment of $633 due in September 2023, however, during the year ended August 31, 2024, the Company defaulted on its monthly payments. During the three months ended November 30, 2024, the Company incurred interest of $5,084 (2023 - $5,084). As of November 30, 2024, the loan is due on demand and the balance owing, including accrued interest was $310,119 (2023 - $305,035). c) Related party loans During the year ended August 31, 2024, the Company received loans totaling $100,600 from its key management personnel. The loans bear no interest and are due on demand (Note 13(d)).

SECURED CONVERTIBLE NOTES PAYAB

SECURED CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Nov. 30, 2024
SECURED CONVERTIBLE NOTES PAYABLE	11. SECURED CONVERTIBLE NOTES PAYABLE As of August 31, 2023, the Company issued multiple tranches of convertible notes with attached warrants, raising total proceeds of $4,024,891. Of this amount, $543,004 was allocated to the warrants using the relative fair value method and recorded as additional paid-in capital. Bifurcation of the conversion feature is not required and the secured convertible notes payable are classified as a single financial liability. These notes have undergone several amendments, setting an interest rate of 10% per annum and extending their maturity dates. By September 30, 2023, $300,000 of the principal had been repaid, and the remaining notes had matured, prompting the Company to enter into negotiations with the noteholders to further extend the maturity dates. On March 15, 2024, a new amendment was finalized, extending the maturity of all defaulted convertible notes to December 31, 2024. The conversion prices were revised to the lesser of 80% of the 20-day average closing price per share (but no lower than $0.20 per share) or $0.50 per share. The interest rate remains 10% per annum. Additionally, on December 4, 2023, the Company issued an additional convertible note with a face value of $50,000. This note bears interest at 10% per annum, matures on December 31, 2024, and is convertible into common shares at $0.20 per share prior to maturity. As at November 30, 2024, the principal outstanding on the convertible notes totaled $3,774,891 (August 31, 2024 - $3,774,891), with accrued interest payable of $1,196,843 (August 31, 2024 - $1,102,729) recorded within accrued liabilities.

EQUITY

EQUITY	3 Months Ended
	Nov. 30, 2024
EQUITY
EQUITY	12. EQUITY a) Common share transactions During the three months ended November 30, 2024: During the three months ended November 30, 2024, the Company entered into an agreement with certain related parties to settle outstanding payables related to prior management and consulting services. Under the terms of the agreement, payables of $214,782 were settled through the issuance of 1,073,912 common shares, with a fair value of $214,782, of which $107 was allocated to common stock and $214,675 was allocated to additional paid in capital. On November 14, 2024, the Company issued a total of 1,950,000 shares of common stock at $0.20 per share generating gross proceeds of $390,000. During the year ended August 31, 2024: The Company issued a total of 10,181,990 shares of common stock at $0.20 per share and 42,000 shares of common stock at $0.072 per share, generating gross proceeds of $2,039,343, of which $50,000 had been received during the year ended August 31, 2023. Of the 10,181,990 shares of common stock issued, 6,000,000 shares were issued to a shareholder under a share purchase agreement, resulting in cash proceeds of $1,199,920 during the year ended August 31, 2024. As part of the agreement, the shareholder has the option to appoint a member to the Board of Directors. The Company incurred a finder’s fee of $70,000 and share issuance costs of $50,000 in connection with these transactions. On August 16, 2024, the Company entered into an agreement with certain related parties to settle outstanding payables related to prior management and consulting services. Under the terms of the agreement, payables of $569,475 were settled through the issuance of 654,568 common shares, with a fair value of $65,457, of which $65 was allocated to common stock and $569,410 was allocated to additional paid in capital. The difference between the settlement amount and the par value of the shares was recognized as an additional capital contribution from the related parties and recorded under additional paid-in capital. b) Share purchase warrants The following table summarizes the continuity of share purchase warrants: Number of warrants Weighted average exercise price # $ Balance, August 31, 2023 5,459,000 1.06 Expired (4,459,000 ) 1.25 Balance, November 30, 2024 and August 31, 2024 1,000,000 0.20 As at November 30, 2024, there were 1,000,000 warrants outstanding. These warrants have exercise price of $0.20 and will expire on July 30, 2025. c) Stock options The Company measures equity-settled share-based payments at fair value on the grant date, recognizing share-based compensation expense over the vesting period based on the estimated number of equity instruments expected to vest and uses Plain Vanilla for calculating the expected terms of options. Any consideration received from stock option exercises is recorded as an increase to common stock and additional paid-in capital. A summary of the Company’s stock option activity is as follows: Number of options Weighted average exercise price Weighted average remaining contractual term Aggregate Intrinsic Value # $ Years $ Outstanding, August 31, 2024 12,640,000 0.21 - Granted 918,750 0.20 - Exercised (1,073,912 ) 0.20 - Expired (1,861,088 ) 0.20 - Outstanding, November 30, 2024 10,623,750 0.22 1.92 - Exercisable, November 30, 2024 8,866,667 0.22 1.43 - A summary of the Company’s outstanding stock options is as follows: Expiry date Number of options Weighted average exercise price Weighted average remaining contractual term # $ Years December 12, 2024 1,900,000 0.20 0.03 January 8, 2025 2,150,000 0.29 0.11 February 1, 2026 2,200,000 0.21 1.17 May 1, 2027 615,000 0.20 2.42 March 8, 2028 2,200,000 0.20 3.27 June 3, 2028 140,000 0.20 3.51 October 1, 2028 200,000 0.20 3.84 March 1, 2029 300,000 0.06 4.25 October 21, 2031 918,750 0.20 6.89 10,623,750 0.22 1.92 During the three months ended November 30, 2024, the Company incurred stock-based compensation of $53,941 from the vesting of stock options (2023 - $500,627). All stock-based compensation was recorded within consulting fees on the consolidated statements of operations and comprehensive loss. Granting of new stock options On March 1, 2024, the Company granted 300,000 options to a consultant with an exercise price of $0.06, expiring on March 1, 2029. The options vest in two equal tranches over six-month intervals. The fair value of these options was estimated at $27,573, using the Black-Scholes model with the following assumptions: stock price of $0.10, expected life of 5 years, risk-free interest rate of 4.17%, volatility of 179%, and no dividend yield. On October 21, 2024, the Company issued 918,750 options at an exercise price of $0.20 per share to a director, as part of his appointment. The options expire 7 years from the issuance date. The fair value of these options was estimated at $46,631, using the Black-Scholes model with the following assumptions: stock price of $0.05, expected life of 5 years, risk-free interest rate of 4.00%, volatility of 201%, and no dividend yield. Granting of performance-based options On January 1, 2024, the Company entered into a performance-based option agreement with a consultant, allowing for the potential vesting of up to 500,000 options upon meeting specified performance conditions. The options vest over a two-year period from the date each milestone is achieved. During the year ended August 31, 2024, 200,000 options were granted following the achievement of performance conditions. These options have an exercise price of $0.20, expire on October 1, 2028, and are scheduled to fully vest by February 13, 2026. On October 1, 2024, the Company amended the agreement to now provide for the grant of up to 700,000 performance-based options between October 1, 2024 and March 31, 2025. Pursuant to the amendment, the consultant will be granted a maximum of 100,000 options each time a sales contract with an annual value of $100,000 is signed. For any contracts with an annual value exceeding $1,500,000, the consultant will be awarded 200,000 options. Options granted pursuant to achievement of performance targets will vest over a two-year period from the date the contract is signed. The fair value of these options was $15,765 and was estimated using the Black-Scholes option pricing model, applying the following weighted average inputs: stock price of $0.085, expected life of 4.75 years calculated based on Plain Vanilla, risk-free interest rate of 3.93%, expected volatility of 178%, and no dividend yield. Modification of options On January 1, 2024, the Company modified the exercise price and vesting terms for 300,000 previously granted and unexercised options as follows: Number of stock options Original exercise price Original vesting terms Modified exercise price Modified vesting terms 300,000 $0.22 100,000 on October 1, 2024 100,000 on October 1, 2025 100,000 on October 1, 2026 $0.20 150,000 on January 1, 2024 150,000 on September 30, 2024 The adjustment was treated as a modification, requiring a remeasurement of the options’ fair value as of the modification date. The fair value was determined using the Black-Scholes option pricing model with the following inputs: stock price of $0.085, expected life of 4.75 years calculated based on Plain Vanilla, risk-free interest rate of 3.93%, expected volatility of 178%, and no dividend yield. This remeasurement resulted in an incremental stock-based compensation expense of $28,129.

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended
	Nov. 30, 2024
RELATED PARTY TRANSACTIONS AND BALANCES
RELATED PARTY TRANSACTIONS AND BALANCES	13. RELATED PARTY TRANSACTIONS AND BALANCES a) Key management compensation through consulting services The Company has identified its key management personnel to include its directors and senior officers. A summary of the compensation provided to key management during the three months ended November 30, 2024 and 2023 is as follows: 2024 2023 Compensation to the Chief Executive Officer (“CEO”) $ 13,072 $ 27,683 Compensation to the ex-Chief Financial Officer (“ex-CFO”) 12,131 23,069 Compensation to the Chief Operations Officer (“COO”) 10,988 23,069 Compensation to the Chief Business Development Officer (“CBDO”) 13,186 70,533 Compensation to the directors 2,500 25,500 $ 51,877 $ 169,854 All compensation provided to key management personnel is made in the normal course of business and is included in consulting fees. b) Stock-based compensation A summary of stock-based compensation from vesting options granted to related parties during the three months ended November 30, 2024 and 2023 is as follows: 2024 2023 Stock-based compensation to the directors $ 46,631 $ 19,628 $ 46,631 $ 19,628 All stock-based compensation is recorded within consulting fees. c) Debt settlements with related parties During the year ended August 31, 2024, the Company entered into a debt waiver agreement with its CEO and COO, under which each officer forgave $75,336 in payables related to past management services. As a result, the Company wrote off a total payable amount of $150,672 and recognized this as a capital contribution from the officers, which was recorded in additional paid-in capital. On August 16, 2024, the Company entered into a debt settlement agreement with certain directors and senior officers. Under the agreement, outstanding payables owed to these individuals were settled through the issuance of the Company’s common shares. The table below summarizes the amounts settled and the number of shares issued to each related party: Settlement with CEO Settlement with COO Settlement with CBDO Settlement with director Total Settlement amount $ 126,500 $ 178,000 $ 114,975 $ 150,000 $ 569,475 Number of shares issued (#) 145,402 204,597 132,155 172,414 654,568 The settlement amount of $569,475 was recognized as capital contribution from the officers and was recorded as equity. The Company entered into a debt settlement agreement with its former CFO and a former director in connection with their termination. Pursuant to the agreement, outstanding amounts payable to these individuals were settled through the issuance of stock options, which were subsequently exercised to acquire common shares of the Company. The following table provides a summary of the amounts settled and the corresponding number of shares issued to each related party.: Settlement with ex- CFO Settlement with ex- director Total Settlement amount $ 127,782 $ 87,000 $ 214,782 Number of shares issued (#) 638,912 435,000 1,073,912 The settlement amount of $214,782 was recognized as capital contribution from the officers and was recorded as equity. d) Amounts due to related parties In the normal course of operations, the Company shares certain administrative resources with entities related by common management and directors. These administrative resources and services are measured at their exchange value. All amounts payable and receivable from related parties are non-interest bearing, unsecured, and due on demand. The following table summarizes the amounts due to related parties: November 30, 2024 August 31, 2024 Trade payables to the CEO $ - $ 17,428 Trade payables to the COO 15,031 4,371 Trade payables to the CFO - 129,309 Trade payable to the CBDO 8,975 7,718 Trade payable to a former director 98,867 194,687 $ 122,873 $ 353,513 During the year ended August 31, 2024, the Company received short-term loans totaling $20,600 from its CBDO and $80,000 from one of its directors. These loans are due on demand and bear no interest (Note 10). The following table summarizes the loans from related parties: November 30, 2024 August 31, 2024 Outstanding short-term loan from the CBDO $ 20,600 $ 20,600 Outstanding short-term loan from a director 75,000 80,000 $ 95,600 $ 100,600

FINANCIAL RISK FACTORS

FINANCIAL RISK FACTORS	3 Months Ended
	Nov. 30, 2024
FINANCIAL RISK FACTORS
FINANCIAL RISK FACTORS	14. FINANCIAL RISK FACTORS The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows: a) Credit risk Credit risk arises when one party to a financial instrument fails to meet its obligations, potentially causing financial loss to the other party. The Company’s main exposure to credit risk lies in its cash holdings and trade receivables. Cash is securely held with major Canadian banks, and trade receivables remain minimal. Management considers the overall credit risk to be low. b) Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. As at November 30, 2024, the Company had a working capital deficiency of $8,874,738 (August 31, 2024 - $8,834,739). To address this risk, the Company has implemented a planning and budgeting process to assess the funding required to support its operations. Limited cash resources have impacted the Company’s ability to meet some obligations as they fall due, including accounts payable, loans payable, and secured convertible notes. Loans payable totaling $2,813,600 are due on demand. During the year ended August 31, 2024, the Company negotiated an extension of its convertible notes’ maturity to December 31, 2024. The Company continues to seek funding through equity offerings or debt financing to meet operational needs, while carefully managing existing cash resources. However, there can be no assurance that future financing will be available or on favorable terms and as a result, liquidity risk is high. c) Interest rate risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to interest rate risk is minimal, as it does not hold any variable-rate financial liabilities. d) Foreign exchange risk Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the Canadian dollar. The Company has not entered into any foreign currency contracts to mitigate risk but manages the risk my minimizing the value of financial instruments denominated in foreign currency. The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Canadian dollars: November 30, 2024 August 31, 2024 Accounts payable and accrued liabilities $ (449,240 ) $ (1,023,380 ) Net exposure in Canadian dollars $ (449,240 ) $ (1,023,380 ) Balance in US dollars $ (332,943 ) $ (758,452 ) As at November 30, 2024, a 10% change in the US dollar to the Canadian dollar exchange rate would impact the Company’s net loss by approximately $33,294 (August 31, 2024 - $75,845). The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Colombian Pesos: November 30, 2024 August 31, 2024 Cash $ 92,105,759 $ 238,480,051 Accounts receivable 336,604,880 200,766,822 Accounts payable and accrued liabilities (505,047,722 ) (496,725,947 ) Net exposure in Columbian Pesos $ (76,337,083 ) $ (57,479,074 ) Balance in US dollars $ (18,234 ) $ (13,730 ) As at November 30, 2024, a 10% change in the US dollar to the Colombian Peso exchange rate would impact the Company’s net loss by approximately $1,823 (August 31, 2024 - $1,373).

CAPITAL MANAGEMENT

CAPITAL MANAGEMENT	3 Months Ended
	Nov. 30, 2024
CAPITAL MANAGEMENT
CAPITAL MANAGEMENT	15. CAPITAL MANAGEMENT The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the business and continue as a going concern. The Company considers capital to be all accounts in equity. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company’s management to sustain future development of the business. The Company has a working capital deficit and requires additional capital to finance its future business plans. The Company is not subject to any externally imposed capital requirements.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Nov. 30, 2024
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	16. COMMITMENTS AND CONTINGENCIES The Company is involved in various claims, litigation and other matters in the ordinary course and conduct of business. Some of these pending matters may take a number of years to resolve. While it is not possible to determine the ultimate outcome of such actions at this time, and inherent uncertainties exist in predicting such outcomes, it is the Company’s belief that the ultimate resolution of such actions is not reasonably likely to have a material adverse effect on its consolidated financial position or results of operations. a) As of November 30, 2024 and August 31, 2024, the Company recorded a contingent liability of $547,190 (CAD$700,000) for expenses in connection with Allied Colombia acquisition, which is included in the balance of accounts payable and accrued liabilities on the consolidated balance sheet. b) The Company has entered into binding lease agreement for agricultural land in Colombia (Note 9). c) In June 2019, AM Biosciences, a subsidiary of the Company, contracted to manufacture a building initially intended for Canadian operations but later designated for potential U.S. operations in Nevada, pending federal legalization of cannabis. On March 30, 2021, Allied US Products LLC, another subsidiary, agreed to purchase two Nevada cannabis cultivation licenses for $150,000, with a $1,350,000 promissory note and assumed liabilities. Tactical Relief LLC, a subsidiary, also signed a 25-year lease with Fiore Subsidiary for a Nevada property to house these buildings. By August 31, 2022, the Company had paid deposits totaling $2,656,695 for the buildings and $150,000 for the licenses, though the buildings were not yet delivered. In December 2022, the Fiore Subsidiary became insolvent, and the leased property was scheduled for a trustee’s sale. The Company filed a lawsuit in Nevada court seeking to halt the sale or obtain damages, filing a lis pendens to assert its claim on the buildings as personal property. Despite these efforts, the sale proceeded, and the buyer claimed ownership of the buildings as part of the property. The Company is currently awaiting a court decision to affirm its ownership. Due to uncertainty in recoverability, a loss on deposit impairment of $2,656,695 and a $150,000 loss on the license advance were recorded for the year ended August 31, 2023, as the purchase agreement was effectively terminated.

NON-CASH ACTIVITIES

NON-CASH ACTIVITIES	3 Months Ended
	Nov. 30, 2024
NON-CASH ACTIVITIES
NON-CASH ACTIVITIES	17. NON-CASH ACTIVITIES A summary of the Company’s non-cash transactions during the three months ended November 30, 2024 and 2023 is as follows: 2024 2023 Shares issued to settle accounts payable and accrued liabilities owed to related parties $ 214,782 $ -

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Nov. 30, 2024
SEGMENT INFORMATION
SEGMENT INFORMATION	18. SEGMENT INFORMATION The Company has two operating segments including: · Allied Colombia, a Colombian based company through which the Company intends to commence commercial production in Colombia. (Allied Colombia) · Allied Corp. which consists of the rest of the Company’s operations (Allied) Factors used to identify the Company’s reportable segments include the organizational structure of the Company and the financial information available for evaluation by the chief operating decision-maker in making decisions about how to allocate resources and assess performance. The Company’s operating segments have been broken out based on similar economic and other qualitative criteria. The Company operates the Allied reporting segment in one geographical area (Canada), and the Allied Colombia reporting segment in one geographical area (Colombia). A summary of the Company’s segment information is as follows: Allied Allied Colombia Total Gross margin $ 7,386 $ 6,225 $ 13,611 Net loss $ (510,261 ) $ (270,030 ) $ (780,291 ) Depreciation and amortization $ 16,621 $ 16,722 $ 33,343 Total asset $ 701,647 $ 1,248,867 $ 1,950,514

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Nov. 30, 2024
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	19. SUBSEQUENT EVENTS On December 1, 2024, the Company granted stock options to a consultant for the purchase of 1,700,000 shares of the Company's common stock. The exercise price of the options was set at $0.05. 850,000 of the options vest after six months and the remaining 850,000 after one year. On December 9, 2024, the Company cancelled 1,000,000 warrants that were previously issued to an officer of the Company and issued 1,000,000 options in place of the warrant cancellation. On December 12, 2024, 2,065,000 outstanding options held by a director of the Company expired pursuant to termination of his contract on September 12, 2024. On January 8, 2025, 2,150,000 outstanding options previously issued to certain Ambassador Contractors of the Company expired following a Director’s Resolution dated August 16, 2024.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Nov. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
Principles of consolidation	These financial statements include accounts of Allied Corp. and its wholly-owned subsidiaries, including AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd. and Allied Colombia. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.
Foreign currency translation	Foreign currency transactions are translated into U.S. dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rate at the reporting date. All differences are recorded in the consolidated statements of income and comprehensive income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. Assets and liabilities of foreign operations are translated into U.S. dollars at year-end exchange rates and any revenue and expenses are translated at the average exchange rate for the year. The resulting exchange differences are recognized in other comprehensive income.
Cash	Cash is comprised of cash on hand, cash held in trust accounts and demand deposits.
Taxes receivable	Taxes receivable represent payments of VAT and are presented as part of other receivables. On a periodic basis, the Company assess recoverability of these balances based on the probability of the Colombian government to reimburse these amounts.
Inventory	Inventory includes work-in-progress and finished goods. Work-in-progress comprises raw materials, supplies, pre-harvest cannabis plants, and diluted crude. Finished goods consist of dried flower, CBD isolates available for sale, and purchased cannabis products. The costs of inventory include but are not limited to labor, utilities, nutrition and irrigation, overhead and the depreciation of manufacturing equipment and production facilities, and amortization of licenses determined at normal capacity. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and rent of grow facility. The Company began production in Colombia in late 2020, when the Company obtained approval for its strains of products. During the current period, certain costs were determined based on the actual usage of production space as compared to the normal predetermined operational production of the facility based on capacity as the Company gradually started to grow products and prepared the facility ready. Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s consolidated balance sheets, statements of net loss and comprehensive loss and statements of cash flows.
Property, plant and equipment	Property, plant, and equipment are recorded at cost, net of accumulated depreciation and impairment losses. Depreciation is calculated on a straight-line basis over the assets’ estimated useful lives, which are as follows: Category Useful life Farm facility and equipment 1 - 10 years Office and computer equipment 5 - 10 years Land equipment 10 years
Intangible assets	Intangible assets consist of licenses, amortized on a straight-line basis over the shorter of their estimated economic life of 10 years or their legal life. Amortization of licenses begins from the acquisition date. The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives.
Impairment of long-lived assets	Long-lived assets include property and equipment, right-of-use assets, and intangible assets with finite useful lives. At each balance sheet date or when triggering events arise, the Company assesses long-lived assets for potential impairment. Assets are grouped at the lowest level of separately identifiable cash flows, or asset groups. Circumstances that may trigger an impairment review include significant declines in the asset's market price, adverse changes in business climate or legal factors, substantially higher than expected acquisition or construction costs, current period or projected operating losses associated with the asset, and expectations of early asset disposal. If impairment indicators are present, the Company conducts an undiscounted cash flow analysis to assess recoverability. Impairment losses are recognized in profit or loss to the extent that an asset’s carrying amount exceeds its fair value.
Leases	At the start of a contract containing a lease, the Company classifies leases other than short-term leases as either operating or finance leases, following the criteria outlined in ASU 2016-02 Leases For both finance and operating leases, right-of-use assets and lease liabilities are initially measured as the present value of future lease payments plus initial direct costs, discounted at the lease's implicit interest rate, or, if not available, the Company’s incremental borrowing rate. Subsequent measurements differ by lease type: · For finance leases, lease liabilities are measured at amortized cost using the effective interest rate method, and right-of-use assets are measured at cost less accumulated amortization, depreciated on a straight-line basis over the lease term. · For operating leases, lease liabilities are measured at the present value of unpaid lease payments, discounted at the original discount rate. Right-of-use assets are adjusted by accumulated amortization, calculated as the difference between the straight-line lease cost (including amortization of initial direct costs) and the periodic accretion of the lease liability. As at November 30, 2024, the Company has one lease which is classified as an operating lease.
Stock-based compensation	The Company measures equity-settled share-based payments at fair value on the grant date, recognizing share-based compensation expense over the vesting period based on the estimated number of equity instruments expected to vest and uses Plain Vanilla for calculating the expected terms of options. Any consideration received from stock option exercises is recorded as an increase to common stock and additional paid-in capital.
Share issuance costs	Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued.
Secured convertible notes payable	Under the simplified guidance of ASU 2020-06, the Company accounts for convertible debt instruments, including its secured convertible notes payable as a single unit of account unless the conversion feature requires bifurcation in accordance with derivative accounting under ASC 815. Secured convertible notes payable are initially recorded at fair value adjusted for issuance costs and subsequently measured at amortized cost using the effective interest method. Convertible note interest expense includes the stated interest rate and any applicable amortized discounts. Upon conversion, the debt's carrying amount is reclassified to equity with no gain or loss recognized.
Financial instruments	Financial instruments represent contracts that create a financial asset for one party and a financial liability or equity instrument for another. Initially, financial instruments are recorded at fair value, reflecting the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Subsequent measurement depends on the classification of the financial instrument, with values measured at either fair value or amortized cost. For instruments measured at fair value, the Company uses quoted market prices when available to determine fair value. Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy, based on the reliability of the lowest level of inputs used in estimating fair values. The three levels of the fair value hierarchy are as follows: Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 - Inputs other than quoted prices that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices); and Level 3 - Inputs that are not based on observable market data. The Company’s financial instruments comprise cash, trade receivables, accounts payable, accrued liabilities, loans payable, and secured convertible notes payable. There are no financial assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet. As of November 30, 2024, the carrying values of the Company’s financial instruments approximate their fair values, primarily due to their short-term maturities.
Revenue Recognition	The Company’s revenue is comprised of sales of cannabis products. The Company’s revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company’s obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company’s product. Sales of products are for cash or otherwise agreed-upon credit terms. The Company’s payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.
Net income (loss) per common share	Net income (loss) per share is calculated in accordance with ASC 260 Earnings per Share Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding.
Income taxes	The Company accounts for income taxes under ASC 740 Income Taxes A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
Related party transactions	Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts.
Significant accounting estimates and judgments	The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company’s ability to continue to as going concern as described in Note 1.
Recent accounting pronouncements	Issuance of ASU 2020-06: In August 2020, the Financial Accounting Standards Board (FASB) issued ASU 2020-06 - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging and Contracts in Entity’s Own Equity (Subtopic 815-40) Additionally, the new standard introduces enhanced disclosures for convertible debt and freestanding instruments indexed to and settled in an entity’s own equity. It also amends the diluted earnings per share guidance, mandating the use of the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2022, and must be applied on a full or modified retrospective basis, with early adoption allowed starting January 1, 2021. Issuance of ASU 2023-07: In November 2023, the FASB issued ASU 2023-07, which introduces improvements to the information that a public entity discloses about its reportable segments and addresses investor requests for more information about reportable segment expenses. The ASU does not change the current guidance related to the identification of operating segments, the determination of reportable segments, or the aggregation criteria. Rather, the new guidance introduces additional disclosure requirements and expands those requirements to entities with a single reportable segment, not just entities with multiple reportable segments. ASU 2023-07 enhances interim disclosure requirements, clarifies the circumstances in which an entity can disclose multiple segment measures of profit or loss, and introduces the significant expense principle, which requires additional disclosure of segment expenses. In addition, the ASU provides new segment disclosure requirements for entities with a single reportable segment and contains other disclosure requirements. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The enhanced segment disclosure requirements apply retrospectively to all prior periods presented in the financial statements. The Company will adopt ASU 2023-07 for effective September 1, 2024 and the effects will be present in the Company’s financial statements the fiscal year ended August 31, 2025 and all interim periods following. The Company has not early-adopted any new accounting standard, interpretation or amendment that has been issued but is not yet effective other than ASU 2020-06. The adoption of ASU 2020-06 did not have a material impact.
Reclassification and change in presentation of comparative figures	Certain amounts on the Condensed Consolidated Interim Statements of Operations and Comprehensive Loss of the prior year have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Nov. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
Schedule of property plant and equipment estimated useful lives	Category Useful life Farm facility and equipment 1 - 10 years Office and computer equipment 5 - 10 years Land equipment 10 years

INVENTORY (Tables)

INVENTORY (Tables)	3 Months Ended
	Nov. 30, 2024
INVENTORY
Schedule of Inventory	November 30, 2024 August 30, 2024 Work in progress $ 104,720 $ 132,508 Finished goods 182,333 128,508 $ 287,053 $ 261,016

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	3 Months Ended
	Nov. 30, 2024
ACCOUNTS RECEIVABLE
Schedule of accounts receivable	November 30, 2024 August 31, 2024 Trade receivables $ 70,585 $ 47,955 Tax receivables 5,354 - $ 75,939 $ 47,955

DEPOSITS AND ADVANCES (Tables)

DEPOSITS AND ADVANCES (Tables)	3 Months Ended
	Nov. 30, 2024
DEPOSITS AND ADVANCES
Schedule of deposits and advances	November 30, 2024 August 31, 2024 Prepayments for construction facility in Colombia $ 17,558 $ 20,668 Total deposits and advances $ 17,558 $ 20,668

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Nov. 30, 2024
PROPERTY, PLANT AND EQUIPMENT
Schedule of property plant and equipment	November 30, 2024 August 31, 2024 Construction in process $ 416,706 $ 419,592 Farm facility and equipment 1,310,889 1,332,215 Office and computer equipment 27,739 29,244 Land equipment 27,227 28,827 1,782,561 1,809,878 Less: accumulated depreciation 609,337 591,767 Property, plant and equipment, net $ 1,173,224 $ 1,218,111

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Nov. 30, 2024
INTANGIBLE ASSETS
Schedule of intangible assets	November 30, 2024 August 31, 2024 Intangible assets $ 4,198,891 $ 4,445,619 Less: accumulated amortization 969,512 1,024,585 Less: accumulated impairment 3,202,230 3,390,396 Intangible assets, net $ 27,149 $ 30,638

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	3 Months Ended
	Nov. 30, 2024
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Schedule of Accounts Payable And Accrued Liabilities	November 30, 2024 August 31, 2024 Trade payable $ 854,232 $ 832,870 Accrued liabilities 1,904,372 1,870,293 $ 2,758,604 $ 2,703,163

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Nov. 30, 2024
LEASES
Schedule of calculating lease liabilities and weighted average	November 30, 2024 August 31, 2024 Weighted average discount rate 15 % 15 % Weighted average remaining lease term 4.67 years 4.92 years
Schedule of components of lease expenses	Operating lease cost: Amortization of right-of-use assets $ 4,583 Interest expense on lease liabilities 4,682 Total operating lease cost $ 9,265
Schedule of maturity of contractual undiscounted liabilities	Year ending August 31, 2025 $ 25,067 2026 35,231 2027 36,606 2028 36,579 2029 34,658 Total minimum lease payments 168,141 Less: amount of lease payments representing effects of discounting (47,151 ) Present value of minimum lease payments 120,990 Less current portion of lease liability (17,239 ) Lease liabilities, non-current portion $ 103,751

LOANS PAYABLE (Tables)

LOANS PAYABLE (Tables)	3 Months Ended
	Nov. 30, 2024
LOANS PAYABLE
Schedule of loans payable	Loan for prefabricated buildings financing Loan for equipment purchase financing Related party loans Other cash advance Total August 31, 2023 $ 1,742,648 $ 284,700 $ - $ - $ 2,027,348 Additions - - 100,600 100,000 200,600 Interest expense 451,358 20,335 - - 471,693 August 31, 2024 2,194,006 305,035 100,600 100,000 2,699,641 Additions - - 1,035 - 1,035 Repayment - - (10,000 ) - (10,000 ) Interest expense 112,840 5,084 5,000 - 122,924 November 30, 2024 $ 2,306,846 $ 310,119 $ 96,635 $ 100,000 $ 2,813,600

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Nov. 30, 2024
EQUITY
Summary of share purchase warrants	Number of warrants Weighted average exercise price # $ Balance, August 31, 2023 5,459,000 1.06 Expired (4,459,000 ) 1.25 Balance, November 30, 2024 and August 31, 2024 1,000,000 0.20
Schedule of Stock Options activity	Number of options Weighted average exercise price Weighted average remaining contractual term Aggregate Intrinsic Value # $ Years $ Outstanding, August 31, 2024 12,640,000 0.21 - Granted 918,750 0.20 - Exercised (1,073,912 ) 0.20 - Expired (1,861,088 ) 0.20 - Outstanding, November 30, 2024 10,623,750 0.22 1.92 - Exercisable, November 30, 2024 8,866,667 0.22 1.43 -
Summary of outstanding stock options	Expiry date Number of options Weighted average exercise price Weighted average remaining contractual term # $ Years December 12, 2024 1,900,000 0.20 0.03 January 8, 2025 2,150,000 0.29 0.11 February 1, 2026 2,200,000 0.21 1.17 May 1, 2027 615,000 0.20 2.42 March 8, 2028 2,200,000 0.20 3.27 June 3, 2028 140,000 0.20 3.51 October 1, 2028 200,000 0.20 3.84 March 1, 2029 300,000 0.06 4.25 October 21, 2031 918,750 0.20 6.89 10,623,750 0.22 1.92
Schedule of modification of exericse prices and maturity dates	Number of stock options Original exercise price Original vesting terms Modified exercise price Modified vesting terms 300,000 $0.22 100,000 on October 1, 2024 100,000 on October 1, 2025 100,000 on October 1, 2026 $0.20 150,000 on January 1, 2024 150,000 on September 30, 2024

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Tables)	3 Months Ended
	Nov. 30, 2024
RELATED PARTY TRANSACTIONS AND BALANCES
Schedule of stock-based compensation	2024 2023 Stock-based compensation to the directors $ 46,631 $ 19,628 $ 46,631 $ 19,628
Summary of compensation provided to key management	2024 2023 Compensation to the Chief Executive Officer (“CEO”) $ 13,072 $ 27,683 Compensation to the ex-Chief Financial Officer (“ex-CFO”) 12,131 23,069 Compensation to the Chief Operations Officer (“COO”) 10,988 23,069 Compensation to the Chief Business Development Officer (“CBDO”) 13,186 70,533 Compensation to the directors 2,500 25,500 $ 51,877 $ 169,854
Schedule of debt settlement agreement	Settlement with CEO Settlement with COO Settlement with CBDO Settlement with director Total Settlement amount $ 126,500 $ 178,000 $ 114,975 $ 150,000 $ 569,475 Number of shares issued (#) 145,402 204,597 132,155 172,414 654,568 Settlement with ex- CFO Settlement with ex- director Total Settlement amount $ 127,782 $ 87,000 $ 214,782 Number of shares issued (#) 638,912 435,000 1,073,912
Schedule of due from related party	November 30, 2024 August 31, 2024 Trade payables to the CEO $ - $ 17,428 Trade payables to the COO 15,031 4,371 Trade payables to the CFO - 129,309 Trade payable to the CBDO 8,975 7,718 Trade payable to a former director 98,867 194,687 $ 122,873 $ 353,513 November 30, 2024 August 31, 2024 Outstanding short-term loan from the CBDO $ 20,600 $ 20,600 Outstanding short-term loan from a director 75,000 80,000 $ 95,600 $ 100,600

FINANCIAL RISK FACTORS (Tables)

FINANCIAL RISK FACTORS (Tables)	3 Months Ended
	Nov. 30, 2024
FINANCIAL RISK FACTORS
Schedule of foreign currency translation	November 30, 2024 August 31, 2024 Accounts payable and accrued liabilities $ (449,240 ) $ (1,023,380 ) Net exposure in Canadian dollars $ (449,240 ) $ (1,023,380 ) Balance in US dollars $ (332,943 ) $ (758,452 ) November 30, 2024 August 31, 2024 Cash $ 92,105,759 $ 238,480,051 Accounts receivable 336,604,880 200,766,822 Accounts payable and accrued liabilities (505,047,722 ) (496,725,947 ) Net exposure in Columbian Pesos $ (76,337,083 ) $ (57,479,074 ) Balance in US dollars $ (18,234 ) $ (13,730 )

NON-CASH ACTIVITIES (Tables)

NON-CASH ACTIVITIES (Tables)	3 Months Ended
	Nov. 30, 2024
NON-CASH ACTIVITIES
Schedule of Non-cash activities	2024 2023 Shares issued to settle accounts payable and accrued liabilities owed to related parties $ 214,782 $ -

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Nov. 30, 2024
SEGMENT INFORMATION
Schedule of segment information	Allied Allied Colombia Total Gross margin $ 7,386 $ 6,225 $ 13,611 Net loss $ (510,261 ) $ (270,030 ) $ (780,291 ) Depreciation and amortization $ 16,621 $ 16,722 $ 33,343 Total asset $ 701,647 $ 1,248,867 $ 1,950,514

NATURE OF OPERATIONS AND GOIN_2

NATURE OF OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Aug. 31, 2024
NATURE OF OPERATIONS AND GOING CONCERN
Net losses	$ (780,290)	$ (836,673)
Working capital deficit	$ (8,874,738)		$ (8,834,739)

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended
	Nov. 30, 2024
Land Equipment [Member]
Estimated useful lives	10 years
Minimum | Farm facility and equipment [Member]
Estimated useful lives	1 year
Minimum | Office and Computer Equipment [Member]
Estimated useful lives	5 years
Maximum | Farm facility and equipment [Member]
Estimated useful lives	10 years
Maximum | Office and Computer Equipment [Member]
Estimated useful lives	10 years

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Nov. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES
Intangible asset estimated useful life	10 years

INVENTORY (Details)

INVENTORY (Details) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
INVENTORY
Work-in-progress	$ 104,720	$ 132,508
Finished goods	182,333	128,508
Total inventory	$ 287,053	$ 261,016

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Aug. 31, 2023
Net realizable value	$ 33,343	$ 35,419
Inventory [Member]
Write-off of inventory	67,977		$ 417,862
Net realizable value	$ 67,977		$ 417,862

ACCOUNTS RECEIVABLE (Details)

ACCOUNTS RECEIVABLE (Details) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
ACCOUNTS RECEIVABLE
Trade receivables	$ 70,585	$ 47,955
Tax receivables	5,354	0
Accounts receivable	$ 75,939	$ 47,955

DEPOSITS AND ADVANCES (Details)

DEPOSITS AND ADVANCES (Details) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
DEPOSITS AND ADVANCES
Prepayments for construction facility in Colombia	$ 17,558	$ 20,668
Total deposits and advances	$ 17,558	$ 20,668

DEPOSITS AND ADVANCES (Details

DEPOSITS AND ADVANCES (Details Narrative) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
Total deposits and advances	$ 17,558	$ 20,668
Prepayments for construction facility in Colombia [Member]
Total deposits and advances	$ 17,558	$ 20,668

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
PROPERTY, PLANT AND EQUIPMENT
Less: accumulated depreciation	$ 609,337	$ 591,767
Property, plant and equipment, net	1,173,224	1,218,111
Property, plant and equipment, gross	1,782,561	1,809,878
Land Equipment [Member]
Property, plant and equipment, gross	27,227	28,827
Construction in progress [Member]
Property, plant and equipment, gross	416,706	419,592
Farm facility and equipment [Member]
Property, plant and equipment, gross	1,310,889	1,332,215
Office and Computer Equipment [Member]
Property, plant and equipment, gross	$ 27,739	$ 29,244

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Aug. 31, 2024
PROPERTY, PLANT AND EQUIPMENT
Depreciation	$ 42,082	$ 56,676	$ 74,814
Depreciation included in inventory	15,173
Foreign currency translation gain loss	$ (40,199)	$ 16,012

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
INTANGIBLE ASSETS
Intangible assets, gross	$ 4,198,891	$ 4,445,619
Less: accumulated amortization	969,512	1,024,585
Accumulated impairment	3,202,230	3,390,396
Intangible assets, net	$ 27,149	$ 30,638

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
INTANGIBLE ASSETS
Amortization expense	$ 1,851	$ 1,437
Impairment expense	0	0
Foreign currency translation gain loss	$ 1,638	$ 388

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
Operating lease cost:
Trade payable	$ 854,232	$ 832,870
Accrued liabilities	1,904,372	1,870,293
Accounts payable and accrued liabilities	$ 2,758,604	$ 2,703,163

LEASES (Details)

LEASES (Details)	3 Months Ended	12 Months Ended
	Nov. 30, 2024	Aug. 31, 2024
LEASES
Weighted average remaining lease term	4 years 8 months 1 day	4 years 11 months 1 day
Weighted average discount rate	15%	15%

LEASES (Details 1)

LEASES (Details 1) - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Operating lease cost:
Amortization of right-of-use assets	$ 4,583
Interest expense on lease liabilities	4,682
Total operating lease cost	$ 9,265	$ 6,610

LEASES (Details 2)

LEASES (Details 2)	Nov. 30, 2024 USD ($)
LEASES
2025	$ 25,067
2026	35,231
2027	36,606
2028	36,579
2029	34,658
Total minimum lease payments	168,141
Less: amount of lease payments representing effects of discounting	(47,151)
Present value of future minimum lease payments	120,990
Less current obligations under leases	(17,239)
Lease liabilities, net of current portion	$ 103,751

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
LEASES
Increase in right-of-use asset and lease liabilities	$ 39,050
Operating lease cost	9,265	$ 6,610
Operating lease payment	$ 8,585	$ 6,610

LOANS PAYABLE (Details)

LOANS PAYABLE (Details) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2024	Aug. 31, 2024
Loans payable beginning balance	$ 2,699,641	$ 2,027,348
Additions	1,035	200,600
Repayment	(10,000)
Interest expense	122,924	471,693
Loans payable ending balance	2,813,600	2,699,641
Loan for prefabricated buildings financing
Loans payable beginning balance	2,194,006	1,742,648
Additions	0	0
Repayment	0
Interest expense	112,840	451,358
Loans payable ending balance	2,306,846	2,194,006
Loan for equipment purchase financing
Loans payable beginning balance	305,035	284,700
Additions	0	0
Repayment	0
Interest expense	5,084	20,335
Loans payable ending balance	310,119	305,035
Related party loans
Loans payable beginning balance	100,600	0
Additions	1,035	100,600
Repayment	(10,000)
Interest expense	5,000	0
Loans payable ending balance	96,635	100,600
Other cash advance
Loans payable beginning balance	100,000	0
Additions	0	100,000
Repayment	0
Interest expense	0	0
Loans payable ending balance	$ 100,000	$ 100,000

LOANS PAYABLE (Details Narrativ

LOANS PAYABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 20, 2020	Nov. 30, 2024	Nov. 30, 2023	Aug. 31, 2024
Monthly interest payments	$ 37,613
Loans amount				$ 100,600
Balloon payment		$ 633
December 17, 2021 [Member]
Borrowed amount		$ 295,543
Interest rate		8%
Interest payment		$ 15,000
Balance owing of debt		310,119	$ 305,035
Interest expense		$ 5,084	5,084
June 2020 [Member]
Debt repayment description		The revised payment terms require monthly payments of $37,613 for the first three months starting July 1, 2022, followed by monthly payments of $66,288 for the remaining period
Borrowed amount		$ 1,253,772
Interest rate		3%
Loan accrued interest payable		$ 112,840	$ 112,840

SECURED CONVERTIBLE NOTES PAY_2

SECURED CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 15, 2024	Sep. 30, 2023	Aug. 31, 2023	Nov. 30, 2024	Aug. 31, 2024	Dec. 04, 2023
Accrued interests				$ 1,904,372	$ 1,870,293
Convertible Note Member
Accrued interests				$ 1,196,843	1,102,729
Repayment of principal debt		$ 300,000
Debt Instrument, Interest Rate				10%
Amount allocated to warrants			$ 543,004
Total proceeds of convertible note			$ 4,024,891
Principal outstanding				$ 3,774,891	$ 3,774,891
One Convertible Note Member
Convertible notes payable						$ 50,000
Debt Instrument, Interest Rate						10%
Conversion price						$ 0.20
Two Convertible Note Member
Debt Instrument, Interest Rate	10%
Conversion price	$ 0.50
Maturity date of convertible notes	Dec. 31, 2024
Description of conversion price	The conversion prices were revised to the lesser of 80% of the 20-day average closing price per share (but no lower than $0.20 per share

EQUITY (Details)

EQUITY (Details)	3 Months Ended
	Nov. 30, 2024 $ / shares shares
Number of warrants, Beginning balance | shares	12,640,000
Ending balance | shares	10,623,750
Weighted average exercise price, Beginning balance | $ / shares	$ 0.21
Weighted average exercise price, Ending balance | $ / shares	$ 0.22
Warrants [Member]
Number of warrants, Beginning balance | shares	5,459,000
Number of warrants, expired | shares	(4,459,000)
Ending balance | shares	1,000,000
Weighted average exercise price, Beginning balance | $ / shares	$ 1.06
Weighted average exercise price, expired | $ / shares	1.25
Weighted average exercise price, Ending balance | $ / shares	$ 0.20

EQUITY (Details 1)

EQUITY (Details 1)	3 Months Ended
	Nov. 30, 2024 USD ($) $ / shares shares
EQUITY
Number of warrants, Beginning balance | shares	12,640,000
Number of options, granted | shares	918,750
Number of options, exercised | shares	(1,073,912)
Number of options, expired | shares	(1,861,088)
Ending balance | shares	10,623,750
Number of options, Exercisable balance | shares	8,866,667
Weighted average exercise price, Beginning balance | $ / shares	$ 0.21
Weighted Average exercise price, granted | $ / shares	0.20
Weighted Average exercise price, exercised | $ / shares	0.20
Weighted Average exercise price, expired | $ / shares	0.20
Weighted Average exercise price, exercisable balance | $ / shares	0.22
Weighted average exercise price, Ending balance | $ / shares	$ 0.22
Weighted average contractual term, outstanding	1 year 11 months 1 day
Weighted average contractual term, exercisable	1 year 5 months 4 days
Aggregate Intrinsic value, Beginning | $	$ 0
Aggregate Intrinsic value, Granted | $	0
Aggregate Intrinsic value, exercisable balance | $	0
Aggregate Intrinsic value, outstanding balance | $	$ 0

EQUITY (Details 2)

EQUITY (Details 2)	3 Months Ended
	Nov. 30, 2024 $ / shares shares
Number of options, | shares	10,623,750
Weighted Average exercise price | $ / shares	$ 0.22
Weighted average contractual term	1 year 11 months 1 day
December 12, 2024 (Member)
Number of options, | shares	1,900,000
Weighted Average exercise price | $ / shares	$ 0.20
Weighted average contractual term	10 days
Febuary 1, 2026 [Member]
Number of options, | shares	2,200,000
Weighted Average exercise price | $ / shares	$ 0.21
Weighted average contractual term	1 year 2 months 1 day
May 1, 2027 [Member]
Number of options, | shares	615,000
Weighted Average exercise price | $ / shares	$ 0.20
Weighted average contractual term	2 years 5 months 1 day
October 1, 2028 [Member]
Number of options, | shares	200,000
Weighted Average exercise price | $ / shares	$ 0.20
Weighted average contractual term	3 years 10 months 2 days
March 1, 2029 [Member]
Number of options, | shares	300,000
Weighted Average exercise price | $ / shares	$ 0.06
Weighted average contractual term	4 years 3 months
January 8, 2025 [Member]
Number of options, | shares	2,150,000
Weighted Average exercise price | $ / shares	$ 0.29
Weighted average contractual term	1 month 9 days
March 8, 2028 (Member)
Number of options, | shares	2,200,000
Weighted Average exercise price | $ / shares	$ 0.20
Weighted average contractual term	3 years 3 months 7 days
June 3, 2028 [Member]
Number of options, | shares	140,000
Weighted Average exercise price | $ / shares	$ 0.20
Weighted average contractual term	3 years 6 months 3 days
October 21, 2031 [Member]
Number of options, | shares	918,750
Weighted Average exercise price | $ / shares	$ 0.20
Weighted average contractual term	6 years 10 months 20 days

EQUITY (Details 3)

EQUITY (Details 3) - Stock Option For Modification [Member]	Jan. 01, 2024 $ / shares shares
Number of stock options for modification of exercise price and vesting term	300,000
Number of stock options for modification of exercise price | $ / shares	$ 0.22
Number of stock options for modified exercise price | $ / shares	$ 0.20
October 1, 2024 [Member]
Number of stock options for modification of vesting terms before modification	100,000
October 1, 2025 [Member]
Number of stock options for modification of vesting terms before modification	100,000
October 1, 2026 [Member]
Number of stock options for modification of vesting terms before modification	100,000
January 1, 2024 [Member]
Number of stock options for modified of vesting terms	150,000
September 30, 2024 [Member]
Number of stock options for modified of vesting terms	150,000

EQUITY (Detail Narrative)

EQUITY (Detail Narrative) - USD ($)		3 Months Ended		12 Months Ended
	Nov. 14, 2024	Nov. 30, 2024	Nov. 30, 2023	Aug. 31, 2024
Share issue price per share	$ 0.20
Warrants outstanding		1,000,000
Warrants exercise price		$ 0.20
Stock Issued During Period, Shares, Purchase Agreement				6,000,000
Stock Issued During Period, Value, Purchase Agreement				$ 1,199,920
Price per share				$ 0.20
Cash received from share subscrptions				$ 50,000
Gross proceeds from issuance of stock	$ 390,000	$ 390,000	$ 0
Number of options, granted		10,623,750
Weighted Average exercise price		$ 0.22
Stock Issued During Period, Shares		1,073,912		10,181,990
Common stock shares issued	1,950,000	115,495,384		112,471,472
Finders fee				$ 70,000
Stock Issuance Costs				50,000
Stock Issued During Period, Value		$ 214,782		$ 2,039,343
Outstanding payables settled		214,782
Additional paid in capital allocated		214,675
Common stock allocated		107
Stock Issued During Period, Value		390,000	0
Stock-based compensation		$ 53,941	143,653
August 16, 2024 [Member]
Stock Issued During Period, Shares		654,568
Stock Issued During Period, Value		$ 65,457
Shares issued to settled related party debts		569,475
Shares issued to settled related party debts to additional paid in capital		569,410
Shares issued to settled related party debts to common stock		$ 65
March 1, 2024 [Member]
Number of options, granted		300,000
Weighted Average exercise price		$ 0.06
Stock-based compensation		$ 27,573
Stock price		$ 0.10
Expected life		5 years
Risk-free interest rate		4.17%
Volatility		179%
October 21, 2024 [Member]
Number of options, granted		918,750
Weighted Average exercise price		$ 0.20
Stock-based compensation		$ 46,631
Stock price		$ 0.05
Expected life		5 years
Risk-free interest rate		4%
Volatility		201%
October 1, 2024 [Member]
Number of options, granted		700,000
Description of amended agreement		the consultant will be granted a maximum of 100,000 options each time a sales contract with an annual value of $100,000 is signed. For any contracts with an annual value exceeding $1,500,000, the consultant
Stock-based compensation		$ 15,765
Volatility		178%
Risk-free interest rate		3.93%
Stock price		$ 0.085
Expected life		4 years 9 months
January 1, 2024 [Member]
Number of options, issued		500,000		200,000
Number of options, granted		200,000
Weighted Average exercise price		$ 0.20
$0.20/share
Stock Issued During Period, Shares				10,181,990
$0.072/share
Share issue price per share				$ 0.072
Stock Issued During Period, Shares				42,000
Stock Option For Modification [Member]
Number of options, granted		300,000
Stock-based compensation		$ 28,129
Volatility		178%
Risk-free interest rate		3.93%
Stock price		$ 0.085
Expected life		4 years 9 months
Stock Option [Member]
Stock-based compensation		$ 53,941	$ 500,627

RELATED PARTY TRANSACTIONS AN_3

RELATED PARTY TRANSACTIONS AND BALANCES (Details ) - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Consulting fees and benefits	$ 51,877	$ 169,854
Director [Member]
Consulting fees and benefits	2,500	25,500
CEO [Member]
Consulting fees and benefits	13,072	27,683
CFO [Member]
Consulting fees and benefits	12,131	23,069
Chief Business Development Officer [Member]
Consulting fees and benefits	13,186	70,533
COO [Member]
Consulting fees and benefits	$ 10,988	$ 23,069

RELATED PARTY TRANSACTIONS AN_4

RELATED PARTY TRANSACTIONS AND BALANCES (Details 1) - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Stock-based compensation	$ 46,631	$ 19,628
Director [Member]
Stock-based compensation	$ 46,631	$ 19,628

RELATED PARTY TRANSACTIONS AN_5

RELATED PARTY TRANSACTIONS AND BALANCES (Details 2) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2024	Aug. 31, 2024
Settlement amount	$ 569,475	$ 569,475
Number of shares issued		654,568
Director [Member]
Settlement amount		$ 150,000
Number of shares issued		172,414
CEO [Member]
Settlement amount		$ 126,500
Number of shares issued		145,402
COO [Member]
Settlement amount		$ 178,000
Number of shares issued		204,597
CBDO [Member]
Settlement amount		$ 114,975
Number of shares issued		132,155

RELATED PARTY TRANSACTIONS AN_6

RELATED PARTY TRANSACTIONS AND BALANCES (Details 3) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2024	Aug. 31, 2024
Number of shares issued		654,568
Settlement amount	$ 569,475	$ 569,475
Ex-CFO [Member]
Number of shares issued		638,912
Settlement amount		$ 127,782
Ex-Director [Member]
Number of shares issued		435,000
Settlement amount		$ 87,000
Total [Member]
Number of shares issued		1,073,912
Settlement amount		$ 214,782

RELATED PARTY TRANSACTIONS AN_7

RELATED PARTY TRANSACTIONS AND BALANCES (Details 4) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
Amounts due from related party	$ 122,873	$ 353,513
Short Term Loan [Member]
Amounts due from related party	95,600	100,600
Former Director [Member]
Amounts due from related party	98,867	194,687
Short Term Loan Director [Member]
Amounts due from related party	75,000	80,000
CEO [Member]
Amounts due from related party	0	17,428
CFO [Member]
Amounts due from related party	0	129,309
COO [Member]
Amounts due from related party	15,031	4,371
CBDO [Member]
Amounts due from related party	8,975	7,718
Short Term Loan CBDO [Member]
Amounts due from related party	$ 20,600	$ 20,600

RELATED PARTY TRANSACTIONS AN_8

RELATED PARTY TRANSACTIONS AND BALANCES (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2024	Aug. 31, 2024
Amounts due from related party	$ 122,873	$ 353,513
Settlement amount	569,475	569,475
Consulting fees		75,336
Related party debt forgiveness		150,672
Director 1 [Member]
Amounts due from related party		80,000
CBDO 1 [Member]
Amounts due from related party		$ 20,600
CFO and Former Director [Member]
Settlement amount	$ 214,782

FINANCIAL RISK FACTORS (Details

FINANCIAL RISK FACTORS (Details) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
Accounts payable and accrued liabilities	$ (2,758,604)	$ (2,703,163)
Foreign Currency Exchange Member
Accounts payable and accrued liabilities	(449,240)	(1,023,380)
Net exposure in Canadian dollars	(449,240)	(1,023,380)
Balance in US dollars	$ (332,943)	$ (758,452)

FINANCIAL RISK FACTORS (Detai_2

FINANCIAL RISK FACTORS (Details 1) - USD ($)	Nov. 30, 2024	Aug. 31, 2024
Accounts receivable	$ 75,939	$ 47,955
Accounts payable and accrued liabilities	(2,758,604)	(2,703,163)
Colombian Peso exchange rate [Member]
Cash	92,105,759	238,480,051
Accounts receivable	336,604,880	200,766,822
Accounts payable and accrued liabilities	(505,047,722)	(496,725,947)
Net exposure in Columbian Pesos	(76,337,083)	(57,479,074)
Balance in US dollars	$ (18,234)	$ (13,730)

FINANCIAL RISK FACTORS (Detai_3

FINANCIAL RISK FACTORS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2024	Aug. 31, 2024	Aug. 31, 2023
Loans payable	$ 2,813,600	$ 2,699,641	$ 2,027,348
Working capital deficit	(8,874,738)	(8,834,739)
Foreign Currency Exchange Rate Member
Impact on Net Loss	$ 33,294	$ 75,845
Exchange rate	10%	10%
Colombian Peso exchange rate [Member]
Impact on Net Loss	$ 1,823	$ 1,373
Exchange rate	10%	10%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Dec. 31, 2022	Mar. 30, 2021	Nov. 30, 2024	Aug. 31, 2024
Contingent liability			$ 547,190	$ 547,190
Loss on deposit impairment	$ 2,656,695
Loss on license advance	$ 150,000
Tactical Relief LLC [Member]
Lease term		25 years
June 2019 [Member]
Payment to acquire licenses			150,000
Payment to acquire building			2,656,695
Payment to Nevada cannabis cultivation licenses			150,000
Promissory note assumed for purchase of licenses			$ 1,350,000

NON-CASH ACTIVITIES (Details)

NON-CASH ACTIVITIES (Details) - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Non-Cash Activities [Member]
Shares issued to settle accounts payable and accrued liabilities owed to related parties	$ 214,782	$ 0

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Aug. 31, 2024
Gross margin	$ 13,611	$ 17,036
Net losses	(780,291)
Net realizable value	33,343	$ 35,419
Total assets	1,950,514		$ 2,114,841
Allied [Member]
Gross margin	7,386
Net losses	(510,261)
Depreciation and amortization	16,621
Total assets	701,647
Allied Colombia [Member]
Gross margin	6,225
Net losses	(270,030)
Depreciation and amortization	16,722
Total assets	$ 1,248,867

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - $ / shares	Jan. 08, 2025	Dec. 12, 2024	Dec. 09, 2024	Dec. 01, 2024
Consultants [Member]
Stock options exercise price per share				$ 0.05
Stock options issued				1,700,000
Stock options vested after six months				850,000
Stock options vested after one year				850,000
Officer [Member]
Warrants cancelled			1,000,000
Stock options issued			1,000,000
Ambassador Contractors [Member]
Number of options shares expired	2,150,000
Director [Member]
Number of options shares expired		2,065,000